INVESTMENT WATCH- Ibnsina Pharma is looking to invest EGP 150-200 mn over the next five years to increase its market share to 26% from a current 19.3%, Managing Director Omar Abdel Gawad tells Al Mal. The new funds would bring the company’s total investments to EGP 700 mn, a target it had announced at the time of its initial public offering last year. Ibnsina plans to grow its distribution network, adding new government contracts (which earned the company EGP 1 bn in 2017), and growing its portfolio through ongoing talks with international med manufacturers, Abdel Gawad adds. The news comes one day after Ibnsina announced signing contract with Novo Nordisk to distribute over 20 SKUs of its diabetes care, haemophilia and growth disorders products in Egypt.
More from Enterprise
Banque du Caire’s blockbuster IPO holds firm against EGX selloff
The IFC and the EBRD are in for USD 100…
Electricity Ministry studies changing how your electricity bill gets calculated
The plan is still under study, and neither of the…
EGX30 sheds 4.43% in October to post its first back-to-back monthly loss of 2026
The benchmark fell 4.43% and the small caps twice as…
DPI closes Egypt-born fintech fund Nclude at USD 112 mn
The final close adds roughly USD 7 mn to a…